Regeneron – Page 2

A closer look at pharmas top patent losses in 2025

4 months ago talkbio0Tagged 2023, 2025, Bayer, competition, Expiration, function, Impact food supplement, Indication of (contextual qualifier), Legal patent, Market, Patent Cliff, Regeneron, Sales - occupational activity

Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023

Federal Circuit ruling allows Amgen’s Eylea biosimilar to stay on the market

4 months ago talkbio0Tagged amgen, Amgen 's, court, Eylea, Eylea biosimilar, Federal Circuit, Market, Pavblu, Regeneron

Market, Amgen ‘s, Pavblu, Amgen, Eylea biosimilar, Regeneron, Federal Circuit, court, Eylea

Truveta Genome Project: A Historic 10M Genome Sequencing Initiative Backed by Regeneron, Illumina, and Leading Health Systems

6 months ago talkbio0Tagged Drug Discovery, genetic sequencing, genome sequencing, Genotype, healthcare analytics, Illumina, phenotypic, Precision Medicine, Regeneron, Truveta

Truveta Genome Project, 10M genome sequencing, Regeneron, Illumina, genetic sequencing, genotypic and phenotypic data, healthcare analytics, drug discovery, personalized medicine.

Regeneron Expands Ophthalmology Portfolio with Acquisition of UK-Based Biotech Oxular

7 months ago talkbio0Tagged Acquisition, biotech, Drug Delivery Systems, Ophthalmology specialty, Oxular, Regeneron, Retinal Diseases, Technology

Regeneron, Oxular, Biotech Acquisition, Ophthalmology, Retinal Disorders, Drug Delivery Technology

Regeneron Acquires UK-Based Eye Drug Developer Oxular

7 months ago talkbio0Tagged Acquisition, eye drug development, Oxular, Regeneron, Retina

Regeneron, Oxular, eye drug development, retinal therapeutics, acquisition

Regeneron Advances Anticoagulant Antibody Pair to Late-Stage Testing

7 months ago talkbio0Tagged Antibodies, Anticoagulants, late-stage testing, Regeneron, REGN7508, REGN9933

Regeneron, anticoagulant, antibody, late-stage testing, Factor XI, REGN7508, REGN9933

Regeneron’s EYLEA HD Succeeds in Phase 3 Trial for Retinal Vein Occlusion, Paving Way for 2025 FDA Submission

7 months ago talkbio0Tagged aflibercept, dosing, Extension, Eylea, Hodgkin Disease, Interval, Phase 3 QUASAR trial, Regeneron, Retinal Vein Occlusion, Submission, United States Food and Drug Administration

EYLEA HD, Aflibercept, Retinal Vein Occlusion (RVO), Phase 3 QUASAR Trial, Extended Dosing Intervals, FDA Submission 2025, Regeneron Pharmaceuticals

Regeneron and Bayer Achieve Phase III Success with High-Dose Eylea for Retinal Vein Occlusion, Paving Way for Label Expansion

7 months ago talkbio0Tagged Bayer, Biosimilars, competition, expansion, Eylea HD, Macular retinal edema, Phase 3 Clinical Trials, Regeneron, Retinal Vein Occlusion

Regeneron, Bayer, Eylea HD, Retinal Vein Occlusion (RVO), Macular Edema, Phase III Trial, Label Expansion, Biosimilar Competition

Dupixent (Dupilumab) Advances Towards FDA Approval for Chronic Spontaneous Urticaria (CSU) in 2025

8 months ago talkbio0Tagged Biologic Medicine, Chronic Spontaneous Urticaria, dupilumab, Dupixent, Inflammation, Regeneron, Review [Publication Type], sanofi, United States Food and Drug Administration

Dupixent, Dupilumab, Chronic Spontaneous Urticaria (CSU), FDA Review, Sanofi, Regeneron, Biologic Medicine, Type 2 Inflammation, H1 Antihistamines

Vabysmo’s Growth Pace Slows in Q3, Still on Track for Dominance in Eye Disease Market

9 months ago talkbio0Tagged Age related macular degeneration, Macular edema due to diabetes mellitus, Market, Regeneron, Roche (company), Vabysmo, Vascular Endothelial Growth Factor A

Vabysmo, Roche, Regeneron, Eylea HD, eye disease market, vascular endothelial growth factor A (VEGF-A) therapy, age-related macular degeneration (AMD), diabetic macular edema (DME).